What It Does: Intuitive Surgical manufactures da Vinci surgical robots, robotic systems enabling surgeons to perform minimally invasive procedures with superior precision. Over 9,000 da Vinci systems are installed globally, performing 7+ million procedures annually. The business model is annuity-like: 80%+ of revenue comes from instruments (disposable tools used per surgery) and services (maintenance, training). da Vinci is the only robot approved for general surgery; competitors (Medtronic, Stryker) are entering but trail in adoption. Intuitive generated $7.3B in FY2024 revenue, growing 13%+, with gross margins exceeding 72%. Operating margins approach 30%.
How the Stock Looks: ISRG trades near $560 with a market cap of $180 billion. The stock has appreciated ~50% in the past 18 months, supported by procedure volume growth and pricing power. Operating margins expanded to 30% in FY2024. Free cash flow exceeds $3B annually. The valuation at 70x forward earnings is elevated but justified by recurring revenue and market leadership. Key catalysts include quarterly procedure volume trends, system placements (especially international), instruments revenue growth, Ion bronchoscopy adoption, and margin expansion guidance.
What Analysts Are Saying: 34 analysts rate ISRG a Buy, with consensus price target of $620. Bullish analysts from Goldman Sachs and Morgan Stanley highlight da Vinci's durable moat (switching costs, learning curve, regulatory barriers) and procedure volume growth acceleration. Ion bronchoscopy (lung cancer diagnosis) is an emerging TAM. Bears at JP Morgan caution on valuation and competitive threats from Medtronic and Stryker. However, analyst consensus is decisively bullish: da Vinci's market position is unassailable, procedure volumes are growing 8%+ annually, and instruments revenue scales with installed base. The stock is a recurring revenue medical device compounder.